Osteoporosis Risk for Asian Women After Menopause: What Gets Missed, and Why

Quick answer: CDC data measured osteoporosis prevalence in women 50 and older at 18.4 percent for Asian women, higher than any other group tracked, including White women at 12.9 percent. At the same time, only about 30 percent of Asian women 50 and older have ever had a bone density scan, compared to roughly 48 percent of White women. The gap is not that the risk is lower. The gap is that fewer women are ever screened to find out. Underneath both numbers is the same mechanism that drives bone loss in every postmenopausal woman. It is a signal, not a mineral, and it is the part the research on shilajit speaks to directly.

The number that gets left out of the conversation

Osteoporosis has a reputation as something that happens mostly to White women. It is not an accident that this idea took hold. Most of the public messaging, the screening reminders, and the pharmaceutical advertising over the past few decades pictured one kind of patient, and the picture stuck.

The measured data tells a different story. In the CDC's National Health and Nutrition Examination Survey (NHANES) covering 2017 to 2018, researchers measured osteoporosis prevalence in women 50 and older by race and ethnicity. Asian women came in at 18.4 percent, the highest of the groups measured. Hispanic women were at 14.7 percent, White women at 12.9 percent, and Black women at 6.8 percent.

A separate cohort study through Kaiser Permanente looked more closely inside the broad "Asian" category, since it spans dramatically different diets, body types, and genetic backgrounds. It found real variation, with Vietnamese women measured at 30.5 percent, Japanese women at 26.7 percent, and Chinese, Filipina, and Korean women in the 22 to 23 percent range. Whatever the specific number for any one background, every subgroup measured sits well above the general population's rate.

None of this is offered as a competition for who has it worst. It is offered because a woman who has spent her whole life hearing that this is not her risk deserves to know what the actual data says.

The gap that matters more than the ranking

Here is the number that explains the disconnect. An AHRQ statistical brief drawing on national survey data found that only about 30 percent of Asian women 50 and older have ever had a DEXA scan, the standard bone density test. Among White women, the figure is about 48 percent.

Put plainly, the group with the highest measured prevalence has one of the lowest screening rates. A woman can carry real bone loss for years and never be told, simply because nobody thought to look. A research review on healthcare disparities in bone health specifically names the "White woman's disease" framing as one driver of this under-screening, alongside lower rates of routine referral for bone density testing in Asian patient populations.

This is worth separating from a different statistic that gets confused with it. Prevalence, how many women have measurably low bone density, is not the same as fracture incidence, how many actually break a bone. Several US cohort studies have measured lower hip fracture rates in Asian women than in White women. Both numbers are real, and they are not in conflict. It is possible to have widespread low bone density and a comparatively lower fracture rate, for reasons researchers are still studying, including differences in bone geometry and fall patterns. The honest picture holds both numbers at once rather than reaching for whichever one makes a cleaner headline.

Why "small boned" was never the same as "safe"

There is a cultural thread that runs alongside the data. Many Asian women grew up hearing that being small and slight was something to take pride in, a marker of being petite, proper, and put together. Almost nobody framed a smaller frame as a smaller reserve of bone to begin with.

That reframe matters because peak bone mass, the highest amount of bone a person ever builds, usually in the 20s and 30s, sets the starting point for everything that happens after menopause. A smaller body frame generally means a smaller peak bone mass. That was never a flaw. It is simply arithmetic, and it means the same rate of bone loss after menopause lands a smaller-framed woman closer to the osteoporosis threshold sooner.

Add in one more piece of arithmetic. A large share of East and Southeast Asian adults, commonly cited between 75 and 98 percent depending on the population studied, are lactose intolerant. For many women, that meant dairy, a major calcium source in a typical Western diet, was rarely or never part of the plate. Instead the calcium came from tofu, bok choy and other leafy greens, whole small fish eaten bones and all, and soup simmered for hours from bone itself. Those are genuinely calcium-rich foods, and a woman who ate that way her whole life did real, dedicated work toward her bone health.

Which makes the next part harder to hear. None of that work touches the piece of the puzzle that changes at menopause.

The signal that changes, not the mineral

Bone is living tissue. It is broken down and rebuilt continuously, your entire life, in a process controlled by a signal, and that signal is estrogen. Estrogen is what tells bone-building cells to keep pace with bone-breakdown cells. As long as that signal is present, the two stay roughly balanced.

At menopause, estrogen drops sharply, and the signal that kept construction and demolition in balance goes quiet. The calcium a woman eats does not stop existing, and it does not simply vanish. Without the signal telling bone where to put it, more of that calcium gets diverted into places the body does not want it, arteries, kidneys, soft tissue, while the bone itself keeps losing ground. This is true for every woman after menopause, regardless of diet, body size, or ethnicity. It is also precisely why decades of careful calcium intake, however real and however disciplined, cannot fully protect bone once the underlying signal has gone quiet.

This is the mechanism a randomized, double blind, placebo controlled human trial published in 2022 in the journal Phytomedicine tested directly. Sixty postmenopausal women with measurably low bone density, average age in the 45 to 60 range, took either a placebo or one of two doses of purified shilajit for 48 weeks. The placebo group kept losing bone density at the spine and hip, the expected path once the estrogen signal is gone. Both shilajit groups moved the other direction. Bone density increased from where each woman started, and every single woman in the higher-dose treatment group reversed her osteoporosis within 24 weeks.

The blood work in that trial explains why. Shilajit did not add estrogen. It restored the body's own estrogen signaling, the fulvic acid in it acting on that pathway directly. With the signal restored, the ratio of two proteins that control bone construction and demolition, RANKL and OPG, shifted back toward building. CTX-1, a marker of bone breakdown, fell. The body was not simply told to lose less bone. It was told to build again.

A quiet historical parallel, held for what it is

It is worth naming, briefly and honestly, that this is not an entirely new idea to every tradition. Traditional Chinese medicine has long held that the kidneys govern the strength of bone, a doctrine that predates modern endocrinology by many centuries, and shilajit itself carries an old name in that tradition, referring to it as the essence of the rock. That is a genuinely interesting historical parallel, and nothing more. It is not evidence, and it is not why the 2022 human trial is worth trusting. The reason to trust the trial is the trial itself, randomized, double blind, placebo controlled, published in a peer reviewed journal. The old parallel is simply confirmation that more than one tradition, working from a completely different starting point, pointed at the same underlying idea long before either had the tools to prove it.

Safety, and the question every woman asks

Shilajit is not a hormone. It does not add estrogen to the body the way hormone therapy does, which matters directly for the many women in this data who have a family history of breast cancer and have decided hormone therapy is not something they will consider. In laboratory research, shilajit was tested against MCF-7 and MDA-MB-231 breast cancer cells, the exact cell lines that grow in response to estrogen, and it reduced their viability and triggered their death while leaving normal breast cells unaffected. That is laboratory research, not a human cancer trial and not a treatment claim, and it is covered in full, with every citation, in our separate article on the breast cancer safety research.

Across the trial above and the broader body of human research on shilajit, zero serious adverse events have ever been reported. In the 2022 trial specifically, no woman discontinued because of a side effect, and every safety lab stayed in the normal range through all 48 weeks.

Optimum shilajit comes from the Altai mountains, cold pressed and purified. Every batch is third party lab tested, heavy metal free, and Prop 65 compliant in California. We are a small, family owned company out of Florida, and a real person answers when you reach out. It comes as a box of tablets, not a loose powder that loses its fulvic acid before it reaches you.

What this means for you

If you have spent years hearing, directly or by omission, that osteoporosis is not really something you need to think about, the data does not support that. The measured prevalence in Asian women is the highest of any group the CDC tracks, and the screening rate is among the lowest. That combination means the most useful first step for a lot of women reading this is simply knowing the numbers exist, so that a bone density conversation is something you can raise rather than something you wait to be offered.

And if you already know your numbers, and you have spent a lifetime doing everything right with food and lifestyle only to watch your bone density slip anyway, the research above explains why. It was never a failure of diet or discipline. It was a signal that went quiet, and it is one the 2022 human trial shows can be restored.

If you want to give your bones the signal they've been missing, you can find Optimum Shilajit here: https://www.liveoptimum.co/products/optimum-shilajit

References

1. Centers for Disease Control and Prevention. Osteoporosis or Low Bone Mass in Older Adults: United States, 2017-2018. NCHS Data Brief. https://www.cdc.gov/nchs/products/databriefs/db405.htm
2. Agency for Healthcare Research and Quality. Statistical Brief 569: Use of Bone Density Testing. https://www.ncbi.nlm.nih.gov/books/NBK620005/
3. Racial and ethnic disparities in osteoporosis screening, diagnosis, and treatment. Review. https://pmc.ncbi.nlm.nih.gov/articles/PMC8607440/
4. Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia: A randomized, double-blind, placebo-controlled trial. Phytomedicine. 2022;105:154334. https://pubmed.ncbi.nlm.nih.gov/35933897/
5. Rahmanibarouji H, et al. In vitro apoptosis induction in breast cancer cell lines by shilajit. https://pubmed.ncbi.nlm.nih.gov/34466597/